Epithelial Healing and Visual Outcomes Using Omega-3 Therapy Before and After Photorefractive Keratectomy (PRK) Surgery (Omega-3)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01059019 |
|
Recruitment Status :
Completed
First Posted : January 29, 2010
Last Update Posted : June 21, 2013
|
Sponsor:
University of California, San Diego
Information provided by (Responsible Party):
David J Schanzlin, University of California, San Diego
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to demonstrate that omega-3 supplement can be use as an adjunct therapy for PRK patients. The investigators believe that omega-3 supplement will reduce the size of persistent epithelial defects (PEDS) and eventually hasten the corneal reepithelialization after PRK surgery. If the outcome of this study proves to be effective, then PRK would be a more attractive option to those seeking refractive treatment.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Refractive Error | Dietary Supplement: Omega-3 Fatty Acid Supplements | Not Applicable |
Dry eye and persistent epithelial defects (PEDS) following LASIK and PRK are one of the most common conditions encountered by refractive surgeons and their patient's today.¹⁻⁴ They are associated with significant clinical morbidity in patients resulting in minor problems such as discomfort, to extreme debilitation such as visual loss. There is no accepted definition of persistent epithelial defect (PED) that includes a time period of recovery. We favor the definition given in one text "… when the epithelium fails to re-grow over a defect within the expected time course.⁵ The causes of PED are diverse, with several definite etiologies' including dry eyes, limbal stem cell deficiency, diabetes mellitus and neurotrophic problems. A variety of treatment modalities have been described for PED. The elimination of predisposing associated risk remains a key factor in the management process. Therefore, to prevent and manage this common disorder it is important to have an understanding of the pathophysiology of dry eye after LASIK and PRK. This includes and understanding of the relationship and interaction between inflammation, sensory denervation and essential fatty acid pathways. Reports of clinical efficacy of anti-inflammatory therapies for treatment of dry eye disease provide direct proof of the principle that inflammation is involved in the etiology of dry eye disease. Research has shown that the omega-3 polyunsaturated fatty acids are some of the most effective natural anti inflammatory agents available. The active ingredients in omega 3, EPA ( Eicosapentanoic acid ) which is a 20 carbon omega 3-fatty acid with 5 double-bonds , and DHA ( docosahexanoic acid )which is 22 carbon omega-3 fatty acid with 6 double bond, both found in certain fish oils enhance the conversion of COX ( cyclooxygenase) to prostaglandin E3. A natural anti inflammatory agent, prostaglandin E3 competitively inhibits the effects of the arachidonic acid conversion to prostaglandin E2, a highly inflammatory substance. Prostaglandin E3 also inhibits the synthesis of TNFα and IL-1β, both of which are inflammatory leukotrienes, also by competitive inhibition.⁶ʹ⁷ By decreasing inflammation and stimulating aqueous tear production in rabbits cAMP has been shown to stimulate aqueous tear secretion in dry eye. Furthermore, by decreasing inflammation and augmenting oil and water layers of the tear film, omega-3 supplementation with fish oil rich in EPA may improve both the lipid and aqueous component of the tear film. This may improve surgical outcomes by stabilizing the tear film, reducing epithelial defects and promoting wound healing
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 17 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Supportive Care |
| Official Title: | Epithelial Healing and Visual Outcomes of Patients Using Omega-3 Supplements as an Adjunct Therapy Before and After Photorefractive Keratectomy (PRK) Surgery |
| Study Start Date : | January 2010 |
| Actual Primary Completion Date : | May 2011 |
| Actual Study Completion Date : | May 2011 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Omega-3 Fatty Acids
| Arm | Intervention/treatment |
|---|---|
|
Sham Comparator: Control
Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients.
|
Dietary Supplement: Omega-3 Fatty Acid Supplements
Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
Other Names:
|
|
Experimental: Treatment
20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day
|
Dietary Supplement: Omega-3 Fatty Acid Supplements
Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
Other Names:
|
Primary Outcome Measures :
- Visual acuity, tear break up time, and corneal uptake will be assessed. Photographs will be taken. Calculation of the area in diameter will be assessed using Adobe Photoshop. Comparisons between each group will be made. [ Time Frame: 2 and 4 days, 1 week, 3 and 6 months. ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 28 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male or female candidate for PRK with refractive error of -1.00 to -6.00
- Male or female 18- 28 (may consider increasing this range) years old and >60 years old post cataract surgery for enhancement.
- Patients without history of diabetes.
- Patients without history of hemorrhagic stroke.
- Patient without history of blood dyscrasia.
- Patient without history of diarrhea, abdominal bloating, and indigestion.
- Patient without history of peptic ulcer disease, gastroesophageal reflux and gastroesophageal reflux disease.
Exclusion Criteria:
- Male or female < 18 years old for PRK.
- Male or female with a refractive error < -1.00 or >-6.00
- Patient with history of diabetes.
- Patient with history of hemorrhagic stroke.
- Patient with history of Blood dyscrasia.
- Patient with history of peptic ulcer disease, gastroesophageal reflux and gastroesophageal reflux disease.
- Patient with history of diarrhea, abdominal bloating and indigestion.
- Pregnant women and women that are lactating (nursing mothers)
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01059019
Locations
| United States, California | |
| UCSD Shiley Eye Center | |
| La Jolla, California, United States, 92037 | |
Sponsors and Collaborators
University of California, San Diego
Investigators
| Principal Investigator: | David J Schanzlin, MD | UCSD Shiley Eye Center |
Publications:
| Responsible Party: | David J Schanzlin, DSchanzlin, University of California, San Diego |
| ClinicalTrials.gov Identifier: | NCT01059019 History of Changes |
| Other Study ID Numbers: |
091487 |
| First Posted: | January 29, 2010 Key Record Dates |
| Last Update Posted: | June 21, 2013 |
| Last Verified: | June 2013 |
Keywords provided by David J Schanzlin, University of California, San Diego:
|
Refractive Surgery PRK Photorefractive Keratectomy Omega 3 Fatty Acids Cornea |
Additional relevant MeSH terms:
|
Refractive Errors Eye Diseases |